InvestorsObserver Gives Bullish Rating to Expensify Inc Stock Despite 15.49% Drop Last Week
August 3, 2023
☀️Trending News
Expensify ($NASDAQ:EXFY) Inc is a leading provider of cloud-based software solutions for businesses of all sizes. The company helps businesses streamline their expense management processes by providing a comprehensive platform for tracking, managing, and reporting on expenses. Despite a 15.49% drop in its stock price last week, InvestorsObserver has given the Expensify Inc stock a Bullish rating in its Sentiment Indicator. This reassessment of the stock comes at a time when investors are questioning the current state of the market with Tuesday being a key day for many stocks. Is now the right time to buy this stock? As a leading provider of expense management solutions, Expensify has established itself as a reliable and trusted partner for businesses of all sizes. The company’s platform is designed to help businesses reduce costs, increase efficiency, and ensure compliance with internal and external regulations.
In addition, Expensify’s customer service team provides personalized support to ensure that customers get the most out of their investment. For those looking to take advantage of the InvestorsObserver bullish rating, Tuesday is the perfect day to make a move. The market may be volatile, but the Expensify stock offers long-term potential and could be an attractive purchase at this time. With a comprehensive platform and customer service team, Expensify has established itself as an industry leader and could be an excellent option for those looking to invest in an expense management solution.
Analysis
GoodWhale is here to analyze the fundamentals of EXPENSIFY. According to our Star Chart, EXPENSIFY has a high health score of 8/10 when it comes to its cashflows and debt, which makes it capable of riding out any crisis without the risk of bankruptcy. We also classified EXPENSIFY as a ‘gorilla’ company, which means that it has achieved a stable and high revenue or earning growth due to its strong competitive advantage. Given its asset strength, growth, medium profitability and weak dividend, we would expect that investors looking for a long-term investment opportunity with a potential for strong returns would be interested in this company. EXPENSIFY’s current fundamentals make it an attractive option for anyone looking for a stable and secure investment. More…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Expensify. More…
| Total Revenues | Net Income | Net Margin |
| 169.23 | -25.58 | -15.1% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Expensify. More…
| Operations | Investing | Financing |
| 29.3 | -2.42 | -8.36 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Expensify. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 217.27 | 114.57 | 1.24 |
Key Ratios Snapshot
Some of the financial key ratios for Expensify are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 28.2% | – | -7.7% |
| FCF Margin | ROE | ROA |
| 15.9% | -8.2% | -3.8% |
Peers
Its main competitors are Thinkific Labs Inc, IODM Ltd, and DocuSign Inc.
– Thinkific Labs Inc ($TSX:THNC)
Thinkific Labs Inc is a Canadian company that provides an online course platform for entrepreneurs, businesses, and individuals. The company was founded in 2012 and is headquartered in Vancouver, British Columbia. As of 2022, the company has a market cap of 281.34M and a ROE of -21.73%. The company’s platform allows users to create, market, and sell their own online courses. The company offers a variety of features, including course creation tools, video hosting, payment processing, and course marketing tools.
– IODM Ltd ($ASX:IOD)
Period is a medical technology company that develops and commercializes innovative products for the treatment of heavy menstrual bleeding, or menorrhagia. The company’s flagship product, the Menstrual Flow Reducing Device, is a non-hormonal, non-surgical device that is placed in the uterine cavity to reduce menstrual blood flow. Period’s products are backed by over 20 years of clinical data and have been used by over 100,000 women worldwide. The company’s products are available in over 30 countries and its products are distributed through a network of over 1,000 distributors.
– DocuSign Inc ($NASDAQ:DOCU)
DocuSign Inc is a company that provides electronic signature technology and digital transaction management services. It has a market cap of 10.09B as of 2022 and a Return on Equity of -15.28%. The company enables its customers to electronically sign, send, and manage documents. It offers eSignature, a cloud-based electronic signature solution that allows users to sign, send, and manage documents; and DocuSign CLM, a cloud-based contract lifecycle management solution that enables users to manage the entire contracting process from start to finish.
Summary
Expensify Inc. is a publicly-traded company on the stock market. Over the past week, the stock has gone down by 15.49%, and is currently rated as “bullish” by InvestorsObserver Sentiment Indicator. Since the stock price dropped the same day, it may be a good idea to do more research before investing.
It’s important to consider the company’s financial health, industry trends, and long-term performance of the stock before buying. Analyzing the history of the stock performance and its current valuation can also help determine whether it is worth investing in Expensify Inc. or not.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
